Mark M. Sieczkarek, Director at NovaBay Pharmaceuticals, Inc. (NBY), bought 25,000 shares at $0.88 ($22K) on 2014-05-19, disclosed to the SEC on 2014-05-21.
Open-market purchase of $22k NBY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| SLTM | BUY | 2013-05-07 | $261K | — | Filing → |
| CPTS | SELL | 2010-02-23 | $1.5M | — | Filing → |
| CPTS | SELL | 2010-01-22 | $2.0M | — | Filing → |